ArticleClinical & translational immunology2024

A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T cells as an off-the-shelf immunotherapy drug against B-cell malignancies.

Dan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.